Published in Cancer Res on February 01, 2007
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Cells of origin in cancer. Nature (2011) 6.85
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 3.56
Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One (2012) 1.93
Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol (2009) 1.89
BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 1.60
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer (2009) 1.48
PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol (2010) 1.47
Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia (2009) 1.46
A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol (2010) 1.46
The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. Genes Dev (2010) 1.45
Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer Cell (2012) 1.26
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol (2012) 1.14
Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop. Neuro Oncol (2011) 1.08
Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res (2012) 1.02
Notch3 activation promotes invasive glioma formation in a tissue site-specific manner. Cancer Res (2011) 1.01
High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol (2011) 1.00
Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. J Neuropathol Exp Neurol (2008) 1.00
Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomas. Neuro Oncol (2010) 0.99
MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. Neuro Oncol (2012) 0.95
Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma. Neoplasia (2008) 0.94
Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis. PLoS One (2010) 0.94
Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle (2012) 0.94
Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 0.91
Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas. J Clin Neurosci (2012) 0.90
Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I. Case Rep Med (2009) 0.89
Microglial control of neuronal activity. Front Cell Neurosci (2013) 0.89
OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J Neurooncol (2010) 0.89
Developmental origins of brain tumors. Curr Opin Neurobiol (2012) 0.89
Comparative characterization of the human and mouse third ventricle germinal zones. J Neuropathol Exp Neurol (2011) 0.88
Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol (2012) 0.87
The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable. PLoS One (2014) 0.87
Cells of origin for cancer: an updated view from prostate cancer. Oncogene (2012) 0.87
Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia (2009) 0.85
Identification of transcriptional regulatory networks specific to pilocytic astrocytoma. BMC Med Genomics (2011) 0.83
Molecular fingerprinting reflects different histotypes and brain region in low grade gliomas. BMC Cancer (2013) 0.82
Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma. Acta Neuropathol Commun (2014) 0.81
Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol (2016) 0.81
A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells. Neoplasia (2016) 0.80
Roles of mTOR Signaling in Brain Development. Exp Neurobiol (2015) 0.80
Evidence for and against regional differences in neural stem and progenitor cells of the CNS. Genes Dev (2010) 0.79
The molecular biology of WHO grade I astrocytomas. Neuro Oncol (2012) 0.79
Spontaneous modifications of contrast enhancement in childhood non-cerebellar pilocytic astrocytomas. Neuroradiology (2012) 0.79
Multi-study integration of brain cancer transcriptomes reveals organ-level molecular signatures. PLoS Comput Biol (2013) 0.79
The taxonomy of brain cancer stem cells: what's in a name? Oncoscience (2014) 0.79
Down-regulation of IKKβ expression in glioma-infiltrating microglia/macrophages is associated with defective inflammatory/immune gene responses in glioblastoma. Oncotarget (2015) 0.79
Signals that regulate the oncogenic fate of neural stem cells and progenitors. Exp Neurol (2013) 0.79
TLX: A master regulator for neural stem cell maintenance and neurogenesis. Biochim Biophys Acta (2014) 0.78
Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol (2015) 0.78
Genetic changes observed in a case of adult pilocytic astrocytoma revealed by array CGH analysis. Mol Cytogenet (2014) 0.77
Comparative transcriptomics reveals similarities and differences between astrocytoma grades. BMC Cancer (2015) 0.77
Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma. Cell Cycle (2017) 0.75
Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features. BMC Cancer (2015) 0.75
Anatomical Involvement of the Subventricular Zone Predicts Poor Survival Outcome in Low-Grade Astrocytomas. PLoS One (2016) 0.75
DNA methylation analysis of paediatric low-grade astrocytomas identifies a tumour-specific hypomethylation signature in pilocytic astrocytomas. Acta Neuropathol Commun (2016) 0.75
Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases. Pathol Oncol Res (2016) 0.75
TLX-Its Emerging Role for Neurogenesis in Health and Disease. Mol Neurobiol (2016) 0.75
MR imaging of brain pilocytic astrocytoma: beyond the stereotype of benign astrocytoma. Childs Nerv Syst (2016) 0.75
Nuclear receptors in neural stem/progenitor cell homeostasis. Cell Mol Life Sci (2017) 0.75
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
International network of cancer genome projects. Nature (2010) 20.35
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
A model of molecular interactions on short oligonucleotide microarrays. Nat Biotechnol (2003) 9.98
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res (2002) 4.27
Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A (2009) 4.17
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
NFKBIA deletion in glioblastomas. N Engl J Med (2010) 3.96
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol (2006) 3.76
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2012) 3.67
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 3.65
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
Neurofibromatosis 2. Curr Opin Neurol (2003) 3.46
Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol (2002) 3.37
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn (2013) 3.36
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res (2006) 3.28
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Histological classification and molecular genetics of meningiomas. Lancet Neurol (2006) 3.19
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res (2005) 3.10
Neurofibromatosis type 1 revisited. Pediatrics (2009) 3.06
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer (2004) 3.05
Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol (2014) 3.01
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol (2009) 3.01
Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res (2004) 2.90
FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem (2002) 2.90
Effect of implementation of a paediatric neurocritical care programme on outcomes after severe traumatic brain injury: a retrospective cohort study. Lancet Neurol (2012) 2.87
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
Cumulative diagnostic radiation exposure in children with ventriculoperitoneal shunts: a review. Childs Nerv Syst (2008) 2.79
Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol (2007) 2.75
Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res (2004) 2.75
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (2010) 2.71
Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res (2006) 2.70
Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation (2009) 2.70
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (2009) 2.67
High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest (2009) 2.66
Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol (2002) 2.65
Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell (2008) 2.65
Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA (2011) 2.61
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev (2011) 2.48
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 2.45
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol (2006) 2.41
Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med (2002) 2.39
Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol (2003) 2.38
O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain (2005) 2.37
Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol (2012) 2.35
Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res (2003) 2.30
Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc Natl Acad Sci U S A (2005) 2.29
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Synergies and distinctions between computational disciplines in biomedical research: perspective from the Clinical andTranslational Science Award programs. Acad Med (2009) 2.25
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol (2012) 2.17
Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res (2007) 2.15
Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases. Am J Ophthalmol (2012) 2.12
Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer (2004) 2.11
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol (2007) 2.11